Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP & Chief R & QA Officer | May 18, 2018 | May 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date May 18, 2018 · Filed May 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,972 |
Reported balance
After 2018-05-18 transaction · row 1
1 source rowRow 1 · 2018-05-18 · Sale · Disposed 25,860 · Balance 107,972 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $50.00 to $50.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $50.00 to $50.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2018 Filed May 21, 2018 18:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 25,860 | $50.03 | $1,293,775.80 |
DisclosureSEC source: 0001209191-18-032073 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,972 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $50.00 to $50.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 16, 2018 Filed May 16, 2018 20:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $46.30 | $13,890.00 |
DisclosureSEC source: 0001209191-18-030724 · doc4.xml · nonDerivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,832 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. Read SEC document |
| May 16, 2018 Filed May 16, 2018 20:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,347 | $46.04 | $200,135.88 |
DisclosureSEC source: 0001209191-18-030724 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,132 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.25 to $46.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2018 Filed May 16, 2018 20:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 4,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030724 · doc4.xml · derivative · entry 4 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F5 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F6 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recepient's termination date. Read SEC document |
| May 15, 2018 Filed May 16, 2018 20:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 4,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030724 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 16:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 22,400 | $40.07 | $897,568.00 |
DisclosureSEC source: 0001209191-18-022904 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,671 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.00 to $40.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,406 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · derivative · entry 12 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 11,406 shares Expires 2021-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F9 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $22.72 | $0.00 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · derivative · entry 11 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2022-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F8 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following December 17, 2015. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 28,848 | $0.00 Strike: $25.15 | $0.00 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · derivative · entry 10 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,194 Underlying: Common Stock · 28,848 shares Expires 2022-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F7 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following January 16, 2015. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 11,103 | $41.10 | $456,333.30 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 9 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,071 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,800 | $40.40 | $113,120.00 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 8 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,174 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.00 to $40.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,170 | $39.53 | $85,780.10 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 7 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,974 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.85 to $39.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 29,980 | $38.23 | $1,146,135.40 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 6 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,144 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.80 to $38.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 31,356 | $37.10 | $1,163,307.60 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 5 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,124 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.75 to $37.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 22,794 | $36.43 | $830,385.42 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 4 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,480 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.70 to $36.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 11,406 | $11.00 | $125,466.00 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 32,500 | $22.72 | $738,400.00 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 20:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 28,848 | $25.15 | $725,527.20 |
DisclosureSEC source: 0001209191-18-021991 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 7,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011669 · doc4.xml · derivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,808 Underlying: Common Stock · 7,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F4 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F5 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recepient's termination date. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 3,604 | $47.05 | $169,568.20 |
DisclosureSEC source: 0001209191-18-011669 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,520 F2 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:23 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011669 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 20:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 3,704 | $41.70 | $154,456.80 |
DisclosureSEC source: 0001209191-18-009409 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,913 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-18-008509 · doc4.xml · derivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-02-06 F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 4,437 | $35.80 | $158,844.60 |
DisclosureSEC source: 0001209191-18-008509 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,617 F3 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008509 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,054 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. F2 · balance_after: Includes 2 shares issued on October 30, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 18:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,290 | $14.20 | $46,718.00 |
DisclosureSEC source: 0001209191-17-061606 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,052 F2 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units. F3 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Unites · Derivative | 7,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061606 · doc4.xml · derivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,019 Underlying: Common Stock · 7,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F5 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F6 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recepient's termination date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061606 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,021 | $14.33 | $43,290.93 |
DisclosureSEC source: 0001209191-17-049447 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,130 F3 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units. F4 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Unites · Derivative | 7,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049447 · doc4.xml · derivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,231 Underlying: Common Stock · 7,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recepient's termination date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049447 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). F2 · balance_after: Includes 1,940 shares issued on May 31, 2017 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 16, 2017 Filed May 17, 2017 16:57 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,873 | $15.25 | $59,063.25 |
DisclosureSEC source: 0001209191-17-033189 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,000 F2 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units. F3 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:57 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Unites · Derivative | 7,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033189 · doc4.xml · derivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,442 Underlying: Common Stock · 7,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F5 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F6 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recepient's termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:57 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033189 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 20:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,059 | $15.96 | $48,821.64 |
DisclosureSEC source: 0001209191-17-011765 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,661 F3 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units. F4 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Unites · Derivative | 7,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011765 · doc4.xml · derivative · entry 3 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,654 Underlying: Common Stock · 7,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recepient's termination date. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011765 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). F2 · balance_after: Includes 822 shares issued on November 30, 2016 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 17:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 49,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008810 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · EVP & Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,687 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 16:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,995 | $19.53 | $58,492.35 |
DisclosureSEC source: 0001209191-16-150862 · doc4.xml · nonDerivative · entry 2 Clark Mitchall G. · CIK 0001612094 · Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,187 F2 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units. F3 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted October 12, 2016. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Unites · Derivative | 7,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150862 · doc4.xml · derivative · entry 3 Clark Mitchall G. · CIK 0001612094 · Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,865 Underlying: Common Stock · 7,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F5 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 17, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F6 · derivative.expiration_date: The earlier of (i) March 27, 2021 or (ii) the recepient's termination date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150862 · doc4.xml · nonDerivative · entry 1 Clark Mitchall G. · CIK 0001612094 · Chief R & QA Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.